Vanguard Group
WST icon

Vanguard Group’s West Pharmaceutical WST Stock Holding History

Quarter Market Value Status Shares Shares
Change %
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$2.04B Buy
9,316,804
+85,083
+0.9% +$18.6M 0.03% 461
2025
Q1
$2.07B Buy
9,231,721
+244,259
+3% +$54.7M 0.04% 447
2024
Q4
$2.94B Sell
8,987,462
-1,509
-0% -$494K 0.05% 357
2024
Q3
$2.7B Buy
8,988,971
+45,112
+0.5% +$13.5M 0.05% 374
2024
Q2
$2.95B Buy
8,943,859
+4,392
+0% +$1.45M 0.06% 330
2024
Q1
$3.54B Sell
8,939,467
-63,165
-0.7% -$25M 0.07% 292
2023
Q4
$3.17B Buy
9,002,632
+104,740
+1% +$36.9M 0.07% 299
2023
Q3
$3.34B Sell
8,897,892
-52,720
-0.6% -$19.8M 0.08% 246
2023
Q2
$3.42B Buy
8,950,612
+17,303
+0.2% +$6.62M 0.08% 249
2023
Q1
$3.1B Sell
8,933,309
-55,100
-0.6% -$19.1M 0.08% 268
2022
Q4
$2.12B Buy
8,988,409
+62,444
+0.7% +$14.7M 0.06% 375
2022
Q3
$2.2B Buy
8,925,965
+92,870
+1% +$22.9M 0.06% 327
2022
Q2
$2.67B Buy
8,833,095
+116,783
+1% +$35.3M 0.08% 276
2022
Q1
$3.58B Buy
8,716,312
+82,459
+1% +$33.9M 0.08% 239
2021
Q4
$4.05B Buy
8,633,853
+103,494
+1% +$48.5M 0.09% 210
2021
Q3
$3.62B Buy
8,530,359
+141,824
+2% +$60.2M 0.09% 216
2021
Q2
$3.01B Sell
8,388,535
-75,950
-0.9% -$27.3M 0.08% 282
2021
Q1
$2.39B Buy
8,464,485
+175,115
+2% +$49.3M 0.06% 336
2020
Q4
$2.35B Sell
8,289,370
-317,920
-4% -$90.1M 0.07% 311
2020
Q3
$2.37B Sell
8,607,290
-12,897
-0.1% -$3.55M 0.08% 252
2020
Q2
$1.96B Buy
8,620,187
+938,852
+12% +$213M 0.07% 299
2020
Q1
$1.17B Buy
7,681,335
+182,222
+2% +$27.7M 0.05% 393
2019
Q4
$1.13B Buy
7,499,113
+105,736
+1% +$15.9M 0.04% 511
2019
Q3
$1.05B Buy
7,393,377
+73,039
+1% +$10.4M 0.04% 503
2019
Q2
$916M Sell
7,320,338
-29,122
-0.4% -$3.64M 0.03% 548
2019
Q1
$810M Buy
7,349,460
+47,872
+0.7% +$5.28M 0.03% 573
2018
Q4
$716M Buy
7,301,588
+233,859
+3% +$22.9M 0.03% 566
2018
Q3
$873M Buy
7,067,729
+139,098
+2% +$17.2M 0.03% 563
2018
Q2
$688M Buy
6,928,631
+104,171
+2% +$10.3M 0.03% 626
2018
Q1
$603M Buy
6,824,460
+36,177
+0.5% +$3.19M 0.03% 662
2017
Q4
$670M Buy
6,788,283
+101,285
+2% +$9.99M 0.03% 622
2017
Q3
$644M Buy
6,686,998
+131,647
+2% +$12.7M 0.03% 613
2017
Q2
$620M Buy
6,555,351
+114,507
+2% +$10.8M 0.03% 608
2017
Q1
$526M Buy
6,440,844
+392,516
+6% +$32M 0.03% 676
2016
Q4
$513M Buy
6,048,328
+152,646
+3% +$12.9M 0.03% 644
2016
Q3
$439M Buy
5,895,682
+180,951
+3% +$13.5M 0.03% 674
2016
Q2
$434M Buy
5,714,731
+194,455
+4% +$14.8M 0.03% 661
2016
Q1
$383M Buy
5,520,276
+198,928
+4% +$13.8M 0.02% 692
2015
Q4
$320M Buy
5,321,348
+46,295
+0.9% +$2.79M 0.02% 756
2015
Q3
$285M Sell
5,275,053
-389,452
-7% -$21.1M 0.02% 787
2015
Q2
$329M Buy
5,664,505
+132,210
+2% +$7.68M 0.02% 766
2015
Q1
$333M Buy
5,532,295
+32,711
+0.6% +$1.97M 0.02% 761
2014
Q4
$293M Buy
5,499,584
+192,217
+4% +$10.2M 0.02% 768
2014
Q3
$238M Sell
5,307,367
-327,003
-6% -$14.6M 0.02% 843
2014
Q2
$238M Buy
5,634,370
+93,403
+2% +$3.94M 0.02% 870
2014
Q1
$244M Buy
5,540,967
+142,573
+3% +$6.28M 0.02% 834
2013
Q4
$265M Buy
5,398,394
+307,073
+6% +$15.1M 0.02% 755
2013
Q3
$210M Buy
5,091,321
+2,758,203
+118% +$114M 0.02% 815
2013
Q2
$164M Buy
+2,333,118
New +$164M 0.02% 884